Navigation Links
Dey Pharma Commemorates 14th Annual Food Allergy Awareness Week
Date:5/10/2011

T INTO YOUR BUTTOCK, as this may not be effective. In case of accidental injection, please seek immediate medical treatment. Epinephrine should be used with caution if you have heart disease or are taking certain medicines that can cause heart-related (cardiac) symptoms.

If you take certain medicines, you may develop serious life-threatening side effects from the epinephrine in EpiPen Auto-Injectors. Be sure to tell your doctor all the medicines you take, especially medicines for asthma. Side effects may be increased in patients with certain medical conditions, or who take certain medicines. These include asthma, allergies, depression, thyroid disease, Parkinson's disease, diabetes, high blood pressure and heart disease.

The most common side effects may include increase in heart rate, stronger or irregular heartbeat, sweating, nausea and vomiting, difficulty breathing, paleness, dizziness, weakness or shakiness, headache, apprehension, nervousness or anxiety. These side effects usually go away quickly, especially if you rest.

For full prescribing information, please click here or visit www.epipen.com.

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

About Dey

Dey Pharma, L.P., a subsidiary of Mylan Inc. (Nasdaq: MYL), is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, severe allergic reactions and psychiatric disorders. The company puts patients first and facilitates efficient, cost-effective partnerships with customers. For more
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Oct. 22, 2014  With a vision to ... medications, a Global Pharmaceutical and Biotech manufacturer selects ... and turnkey solution to protect their animal health ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... serialized and aggregated by the Xyntek and Antares ...
(Date:10/22/2014)... Calif. , Oct. 21, 2014 Influenza will ... flu-associated deaths in the United States ... viruses are thought to spread is from person to person ... Ebola has a serve way of death, but kills much ... Ebola is also done by human fluids including sweat, saliva, ...
(Date:10/22/2014)... Va. and AUSTIN, Texas ... Inc. and PureMHC LLC today announced they have ... develop novel antibody-based immunotherapies designed to target cancers. ... of phosphorylated peptides displayed on the surfaces of ... phosphopeptide tumor targets (PTTs), derived from proteins that ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2WholeHealth Products is proud to be releasing its Influenza A and B combo test, on the heels of the announcing of its phase 2 completion of the Rapid Ebola Test 2Biotech Companies To Co-Discover And Co-Develop Antibodies Targeting Novel Phosphopeptide Tumor Targets 2
... Calif., Aug. 19 Burton Medical, Inc., the leader ... Burton LE-35  to deliver superior illumination, improved reach, and ...  The 35-watt LE-35 provides two to five times more ... improving efficacy and visibility.  This task light provides illuminance ...
... Md., Aug. 19 Novavax, Inc. (Nasdaq: NVAX ... press briefing by U.S. Health and Human Services Secretary Kathleen ... plan to accelerate the development of drugs and vaccines to ... statement of support for the plan,s five key initiatives: ...
Cached Medicine Technology:NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 2NOVAVAX Endorses New U.S. Initiatives to Develop Medical Countermeasures 3
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... HealthDay Reporter TUESDAY, Oct. ... in vitro fertilization (IVF) -- the incubation of embryos in ... device inside the vagina, new research suggests. Scientists from ... an INVOcell, might sharply cut costs for pricey IVF procedures ... accessible to those who don,t live near big-city assisted reproduction ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... October 20, 2014 ASCNYC (ascnyc.org) ... that helps New Yorkers living with HIV/AIDS and ... health, housing, recovery and self-sufficiency. Each year, ASCNYC ... local community through their tireless efforts. , ... Shapses , has been selected as this year’s ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
Breaking Medicine News(10 mins):Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3
... Ind., May 7 Conseco, Inc. (NYSE: ... regulators and two of,its insurance subsidiaries: Conseco Senior ... Company. The settlement concludes a,multistate market conduct examination ... to long-term care claims practices and,procedures, complaint handling, ...
... May 7 Yesterday H. Con.,Res. 342 was introduced ... opposing the Food and Drug Administration,s (FDA) decision to,restrict ... by women to alleviate the symptoms of menopause. The ... pharmacies in January asking them to,cease and desist with ...
... were missed, more doses taken on time , , WEDNESDAY, May ... are less likely to miss doses when reminded by an ... and announces the number of pills to take and how ... was funded by the National Institute on Aging, was presented ...
... AFL ) announced today that it will webcast its annual Financial,Analysts ... operations in Japan and in the United States as well as ... as,follows:, Wednesday, May 14, 2008 8:00 p.m. ... Daniel P. Amos, Chairman & ...
... May 7 Amneal Pharmaceuticals is pleased,to announce ... Primidone,Tablets (50/250mg), Cyclobenzaprine Tablets (10mg) and Demeclocycline,Tablets (150/300mg) ... products,were filed during 2007 using the FDA,s evolutionary ... months., Demeclocycline HCl Tablets USP, in strengths ...
... NHS Choices ( http://www.nhs.uk ), the new,digital ,front ... Well bundle aimed to,help people stay healthy during ... information, the Live Well Travel health guide,( http://www.nhs.uk/livewell/travelhealth/Pages/Travelhealthhome.aspx ... and provides them,with clinically approved guidance to help ...
Cached Medicine News:Health News:Conseco Reaches Settlement of Multistate Market Conduct Examination 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 2Health News:Electronic Pillbox Helps Seniors Stick to Drug Regimens 3Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 2Health News:Aflac Incorporated to Webcast 2008 Financial Analysts Briefing 3Health News:Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format 2
Multispot HIV-1/HIV-2 is a rapid indirect EIA using recombinant and peptide antigens for simultaneous detection and differentiation of anti-HIV-1 and anti-HIV-2 antibodies in human serum or plasma....
Bio-Rad's Genetic Systems™ HBsAg EIA 3.0 screening and confirmatory assays offer outstanding sensitivity and early detection of HBV infection, helping to meet your testing criteria....
The most compact revolutionary innovation in hematology. 3 Part DIFF + CRP measurement on whole blood....
... Evolis™ is a self contained microplate ... based EIA assays. The system is dedicated ... encountered in todays busy laboratory. The system ... of EIA assays that satisfy their microplate ...
Medicine Products: